NCT06141031 2026-03-17
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine
Phase 1 Active not recruiting
Clinical Trials
279 trialsNCT07457541 2026-03-12
Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI
Tomsk National Research Medical Center of the Russian Academy of Sciences
Phase 1 Active not recruiting
NCT03875820 2026-03-10
FRAME
Institute of Cancer Research, United Kingdom
Phase 1 Active not recruiting
NCT06648434 2026-02-20
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine
Phase 1 Recruiting
NCT07117032 2026-02-19
Simulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy (SBRT) in Participants With Cancer-Related Celiac Pain
Case Comprehensive Cancer Center
Phase 1 Not yet recruiting
NCT02021422 2026-02-18
A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy
Baylor Research Institute
Phase 1 Completed
NCT03065062 2026-02-13
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Suspended
NCT06378047 2026-02-09
Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT06203821 2026-02-05
Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer
University of Rochester
Phase 1 Not yet recruiting
NCT06217666 2026-02-05
Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)
University of Rochester
Phase 1 Not yet recruiting
NCT07114939 2026-02-02
FTT PET/CT in Pancreatic Neuroendocrine Tumors
Abramson Cancer Center at Penn Medicine
Phase 1 Recruiting
NCT03323944 2026-01-30
CAR T Cell Immunotherapy for Pancreatic Cancer
University of Pennsylvania
Phase 1 Terminated
NCT02432963 2026-01-28
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
Phase 1 Active not recruiting
NCT06821048 2026-01-23
Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
Zhejiang University
Phase 1 Recruiting
NCT06898385 2026-01-08
IX001 TCR-T
Sun Yat-sen University
Phase 1 Recruiting
NCT04161755 2026-01-07
Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT06065371 2025-12-19
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Henry Ford Health System
Phase 1 Recruiting
NCT06411691 2025-12-18
KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Recruiting
NCT05220046 2025-12-17
Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers
University of Nebraska
Phase 1 Active not recruiting
NCT06199466 2025-12-08
A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT03257761 2025-12-05
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
University of Southern California
Phase 1 Active not recruiting
NCT04117087 2025-12-03
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT05013216 2025-12-03
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Recruiting
NCT05034627 2025-11-28
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 1 Active not recruiting
NCT02639026 2025-11-25
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT05417386 2025-11-18
FOLFIRINOX + NIS793 in Pancreatic Cancer
Massachusetts General Hospital
Phase 1 Terminated
NCT02495896 2025-11-10
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT05111353 2025-11-05
Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery
Washington University School of Medicine
Phase 1 Completed
NCT04484909 2025-10-27
NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT01852890 2025-10-24
Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I
University of Iowa
Phase 1 Completed
NCT05497778 2025-10-14
A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT00885066 2025-09-30
Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer
Centre Antoine Lacassagne
Phase 1 Completed
NCT06533332 2025-09-18
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
EtiraRx Australia Pty Ltd
Phase 1 Recruiting
NCT07173374 2025-09-15
SCART-P
Shandong Cancer Hospital and Institute
Phase 1 Not yet recruiting
NCT03454035 2025-09-11
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT05737615 2025-09-04
PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9
Memorial Sloan Kettering Cancer Center
Phase 1 Withdrawn
NCT07132541 2025-09-02
NBCA
Minia University
Phase 1 Recruiting
NCT06508307 2025-08-21
A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
GONGCHU Biotechnology Co., Ltd
Phase 1 Recruiting
NCT07118176 2025-08-12
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT06048367 2025-08-03
CNSI-Fe(II)
Sichuan Enray Pharmaceutical Sciences Company
Phase 1 Completed
NCT05634525 2025-07-25
Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT06205849 2025-07-25
Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer
University of California, San Diego
Phase 1 Recruiting
NCT05141513 2025-07-18
Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Recruiting
NCT05055323 2025-07-15
A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer
Thomas Jefferson University
Phase 1 Active not recruiting
NCT05277766 2025-07-01
PIPAC-NAL-IRI
University Hospital, Ghent
Phase 1 Recruiting
NCT04477343 2025-06-05
A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
University of Rochester
Phase 1 Recruiting
NCT05440942 2025-06-05
Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma
University of Miami
Phase 1 Completed
NCT06816823 2025-06-04
CAR-NK Cells (CL-NK-001) in Pancreatic Cancer
Changhai Hospital
Phase 1 Recruiting
NCT04137536 2025-05-15
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting